证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 投资者关系活动记录表 编号：2024-012 | --- | --- | --- | --- | |-----------------------------------------------|------------------------------|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活 | £ | 特定对象调研 □分析师会议 □媒体采访 | | | 动类别 | □ □ | 业绩说明会 □新闻发布会 ☑路演活动 现场参观 □其他（券商策略会） | | | 参与单位名称 及人员姓名 | | 少芳；大家资产：钱怡、吴斌；南方基金：钟贇。 | 金鹰基金：欧 ...

证券代码：688253 证券简称：英诺特 公告编号：2024-045 北京英诺特生物技术股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/3 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 5,000 万元~10,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 2.59 | | 累计已回购股数占总股本比例 | 0.0190% | | 累计已回购金额 | 93.30 万元 | | 实际回购价格区间 | 35.93 元/股~36.00 元/股 | 一、 回购股份的基本情况 2024 年 8 月 2 日，公司召开第二届董事会第五次会议，会议审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自 ...

Investment Rating - The report maintains a Buy-A rating for the company with a 6-month target price of 49.85 RMB, implying an 18x forward P/E ratio for 2024 [3][6] Core Views - The company's respiratory business remains highly prosperous, with profitability continuing to improve [1] - The company achieved revenue of 421 million RMB in H1 2024, up 88.3% YoY, with core non-COVID respiratory testing products contributing 412 million RMB, up 160.1% YoY [1] - Net profit attributable to shareholders reached 206 million RMB in H1 2024, a 166.5% YoY increase [1] - The company is actively expanding its overseas business, with Southeast Asia as the initial focus, replicating its successful domestic marketing strategy [3] Financial Performance - Gross margin reached 81.6% in H1 2024, up 5.6 percentage points from 2023, while net profit margin improved to 49.0%, up 12.6 percentage points [2] - In Q2 2024, revenue grew 56.6% YoY to 139 million RMB, with net profit up 155.1% YoY to 60 million RMB [1] - The company's inventory turnover days and accounts receivable turnover days were approximately 123 days and 36 days, respectively, in H1 2024 [1] Business Development - The company is deepening its presence in the respiratory pathogen testing and pediatric pathogen testing markets, focusing on key tertiary hospitals and children's hospitals while expanding into grassroots medical institutions [1] - Overseas expansion is progressing, with a wholly-owned subsidiary established in Singapore as the international headquarters, and multiple products already approved or in the process of approval in overseas markets [3] Future Outlook - Revenue is expected to grow 64.3%, 34.4%, and 29.9% YoY in 2024-2026, respectively [6] - Net profit attributable to shareholders is projected to increase 116.6%, 32.8%, and 29.2% YoY in 2024-2026, respectively [6] - The company's strong growth potential is supported by its leading position in the respiratory testing market and its expanding international presence [3][6]

证券代码：688253 证券简称：英诺特 公告编号：2024-040 北京英诺特生物技术股份有限公司关于调整公司 2023 年限制性股票激励计划授予价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京英诺特生物技术股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开了第二届董事会第六次会议、第二届监事会第六次会议，审议通过了《关 于调整公司 2023 年限制性股票激励计划授予价格的议案》，现将有关事项说明 如下： 一、 本次限制性股票激励计划已履行的决策程序和信息披露情况 （一）2023 年 8 月 27 日，公司召开第一届董事会第十八次会议，审议通过 了《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公 司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大 会授权董事会办理公司 2023 年限制性股票激励计划相关事宜的议案》等相关议 案。公司独立董事就上述涉及发表独立意见事项发表了明确同意的独立意见。 （二）2023 年 8 月 29 日，公 ...

证券代码：688253 证券简称：英诺特 公告编号：2024-041 公司《2023 年限制性股票激励计划（草案）》（以下简称"本次激励计划"、 "本激励计划"或"《激励计划》"）及其摘要规定的限制性股票预留授予条件 已经成就，根据公司 2023 年第一次临时股东大会授权，公司于 2024 年 8 月 28 日召开第二届董事会第六次会议、第二届监事会第六次会议，审议通过了《关于 向公司 2023 年限制性股票激励计划激励对象授予预留部分限制性股票的议案》， 同意确定 2024 年 8 月 28 日为预留授予日，并同意以调整后的授予价格 13.20 元 /股的授予价格向符合授予条件的 20 名激励对象授予 30.00 万股限制性股票。现 将有关事项说明如下： 一、限制性股票授予情况 （一）本次限制性股票授予已履行的决策程序和信息披露情况 （一）2023 年 8 月 27 日，公司召开第一届董事会第十八次会议，审议通过 了《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公 1 / 9 限制性股票预留授予日：2024 年 8 月 28 日。 限制性股票预留授予数量：30.00 万股，约占本 ...

公司简称：英诺特 证券代码：688253 $$-\sqrt[4]{x}$$ 上海荣正企业咨询服务（集团）股份有限公司 关于 北京英诺特生物技术股份有限公司 2023 年限制性股票激励计划 预留授予事项 之 独立财务顾问报告 2024 年 8 月 | 二、声明 | 4 | | --- | --- | | 三、基本假设 | 5 | | 四、本次限制性股票激励计划的审批程序 | 6 | | 五、本次限制性股票的预留授予情况 | 8 | | 六、独立财务顾问意见 | 10 | | （一）本次实施的股权激励计划与股东大会审议通过的股权激励计 划的差异情况 | 10 | | （二）本次限制性股票预留授予条件说明 10 | | | （三）本次限制性股票的预留授予日 11 | | | （四）实施本激励计划对相关年度财务状况和经营成果影响的说明 11 | | | （五）独立财务顾问的核查意见 11 | | | 七、备查文件及咨询方式 | 12 | | （一）备查文件 12 | | | （二）咨询方式 12 | | | 英诺特、本公司、公 司、上市公司 | 指 | 北京英诺特生物技术股份有限公司 | | --- | --- | ...

北京市中伦律师事务所 关于北京英诺特生物技术股份有限公司 2023 年限制性股票激励计划授予价格调整 及预留部分限制性股票授予事项的 法律意见书 $$\Xi{\cal O}{\underline{{{-|\Pi|}}}}\not\Xi J\backslash J\!\!\!\!\!\slash$$ 北京市中伦律师事务所 关于北京英诺特生物技术股份有限公司 2023 年限制性股票激励计划授予价格调整 及预留部分限制性股票授予事项的 法律意见书 致：北京英诺特生物技术股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受北京英诺特生物技术股份有 限公司（以下简称"英诺特"或"公司"）委托，就公司 2023 年限制性股票激励计 划（以下简称"激励计划"或"本激励计划"）相关事宜担任专项法律顾问，并就本 激励计划出具本法律意见书。 为出具本法律意见书，本所律师审阅了《北京英诺特生物技术股份有限公司 2023 年限制性股票激励计划（草案）》（以下简称"《激励计划（草案）》"）、《北 京英诺特生物技术股份有限公司 2023 年限制性股票激励计划实施考核管理办 法》（以下简称"《考核办法》"）、《北京英诺特生物技术股份 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2024, representing a 20% increase compared to the same period last year[1]. - The company projects a revenue guidance of 1.2 billion CNY for the full year 2024, reflecting an expected growth rate of 25%[1]. - The company reported a revenue of RMB 100 million for the first half of 2024, representing a 20% increase compared to the same period in 2023[12]. - The company expects a revenue guidance of RMB 250 million for the full year 2024, which would represent a 25% year-over-year growth[12]. - The company's operating revenue for the first half of 2024 reached CNY 421,061,078.12, representing an 88.33% increase compared to CNY 223,578,854.88 in the same period last year[17]. - Net profit attributable to shareholders was CNY 206,262,255.01, a significant increase of 166.45% from CNY 77,411,834.30 year-on-year[17]. - The gross margin for the first half of 2024 improved to 60%, up from 55% in the same period last year, reflecting better cost management[12]. - The company's operating profit reached 239.69 million RMB, reflecting a growth of 164.23% year-on-year[55]. - The company reported a total comprehensive income of RMB 203,375,875.00 for the first half of 2024, compared to RMB 78,852,331.36 in the same period of 2023, reflecting a growth of 158.5%[157]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching 1.2 million users by the end of June 2024[1]. - User data indicates a growth in the customer base by 15%, reaching a total of 1.5 million users by June 30, 2024[12]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[1]. - Market expansion plans include entering two new international markets by the end of 2024, aiming for a 10% market share in each[12]. - The company is actively expanding its overseas market presence, aiming to make it a second growth engine, but faces legal and regulatory risks[49]. Research and Development - Research and development expenses increased by 30% to 100 million CNY, focusing on innovative therapies and technologies[1]. - The company is investing in R&D for advanced diagnostic technologies, with a budget allocation of RMB 20 million for 2024[12]. - The total R&D investment for the current period is ¥44,212,348.11, representing a 95.07% increase compared to ¥22,664,630.31 in the same period last year[33]. - The company has increased its R&D investment as a percentage of operating revenue to 10.50%, up from 10.14% year-on-year[18]. - The company has established six major technology platforms to enhance its R&D capabilities, ensuring a steady pipeline of new products[38]. Product Development and Innovation - New product launches include a groundbreaking biopharmaceutical that is expected to enter the market by Q4 2024, with projected sales of 300 million CNY in the first year[1]. - New product launches include a respiratory testing kit that has received regulatory approval, expected to contribute significantly to future revenues[12]. - The company focuses on the development, production, and sales of POCT rapid diagnostic products, particularly in the field of respiratory pathogen detection[23]. - The company aims to establish itself as a leading brand in rapid joint detection of respiratory pathogens in China[23]. - The company has developed a multi-antibody detection technology that allows simultaneous testing of two antibodies using a single sample[28]. Financial Health and Cash Flow - The net cash flow from operating activities surged to CNY 157,079,520.23, up 1,795.21% from CNY 8,288,226.80 in the previous year[17]. - The company's cash and cash equivalents increased by 184.51% to ¥473,609,694.67, driven by higher sales returns and maturing bank financial products[60]. - The total amount of receivables decreased by 37.78% to ¥65,443,617.36, due to effective collection efforts and provisions for bad debts[60]. - The company reported a significant reduction in contract liabilities by 68.61% to ¥31,597,710.42, indicating changes in the timing of product sales and prepayments[61]. - Cash inflows from operating activities reached ¥397,576,298.70, up from ¥175,973,265.72 in the first half of 2023, indicating a growth of approximately 126.5%[162]. Governance and Compliance - The board confirmed that there are no significant governance issues affecting the integrity of the financial report[1]. - The company has a robust internal control and governance system to ensure timely and accurate information disclosure, enhancing its market image[41]. - The company has committed to strict execution of its statements and promises made in the IPO prospectus[113]. - The company has taken measures to strengthen internal supervision and management following the warning from the regulatory authority[116]. - The financial report was approved by the board of directors on August 28, 2024, ensuring compliance with regulatory standards[179]. Environmental Responsibility - The company has established an environmental protection mechanism and strictly adheres to national and regional environmental laws and regulations[78]. - The company has a long-term commitment to environmental responsibility and has not faced administrative penalties for environmental issues during the reporting period[79]. - The company has implemented carbon reduction measures, although specific metrics on CO2 equivalent reductions were not applicable[79]. - The company has a structured approach to managing waste generated during production, inspection, research, and storage activities[78]. - The company does not directly emit greenhouse gases, with indirect emissions primarily from electricity used in daily operations[80]. Strategic Acquisitions and Partnerships - The company has completed a strategic acquisition of a biotech firm for 200 million CNY, enhancing its product pipeline[1]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a focus on companies in the diagnostics sector[12]. - A new strategic partnership has been established with a leading healthcare provider to enhance distribution channels and increase market penetration[12]. - The company is considering strategic acquisitions to enhance its market position, with a budget of $100 million allocated for potential deals[86]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company faces risks related to management due to rapid business scale expansion, which may affect operational efficiency[46]. - The company is actively addressing the risks of technology upgrades and new product development, which are critical for maintaining its competitive edge[43]. - The company has established stable relationships with key raw material suppliers, but any adverse changes could impact profitability[47]. - The company has reported a significant increase in revenue for the first half of 2024, with a year-over-year growth of 25%[86].

公司拟使用额度不超过人民币 3.5 亿元（含本数）的闲置募集资金进行现金 管理，在额度范围内可循环滚动使用。 华泰联合证券有限责任公司 关于北京英诺特生物技术股份有限公司 使用暂时闲置募集资金进行现金管理事项的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为 北京英诺特生物技术股份有限公司（以下简称"英诺特"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、《上 海证券交易所科创板股票上市规则》及《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》等相关规定，对英诺特使用暂时闲置募集资金进行 现金管理的事项进行了审慎核查，具体情况如下： 一、投资情况概述 （一）投资目的 为进一步规范公司募集资金的使用与管理，在不影响募集资金投资项目及使 用计划正常进行的前提下，合理利用暂时闲置募集资金进行现金管理，提高募集 资金使用效率，不会影响公司主营业务的正常发展。 （二）投资金额 （三）资金来源 1、资金来源 公司闲置募集资金。 2、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 4 月 ...

证券代码：688253 证券简称：英诺特 公告编号：2024-037 北京英诺特生物技术股份有限公司 2024 年半年度募 集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京英诺特生物技术股份有限公司（以下简称"公司"）根据中国证券监督 管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》《上海证券交易所科创板股票上市规则》以及《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等有关规定，现将公司 2024 年半年 度募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 4 月 28 日作出的《关于同意北京英诺特生物技术股份有限公司首次公开发行股票注册的 批复》（证监许可[2022]902 号），并经上海证券交易所同意，公司于 2022 年 7 月 首次向社会公开发行人民币普通股（A 股）股票 34,020,000 股，每股面 ...